ACTIVITY AIMED FOR AT THE ASSESSMENT OF MEDICINE SAFETY INFORMATION.

Pharmacovigilance includes all the activities designed to evaluate the information associated to the safety of pharmaceutical products, and to ensure that a favourable benefit/risk ratio is maintained for all marketed medicinal products.
The Pharmacovigilance department of the Pharmaceutical Company is therefore responsible to collect and analyze any report of adverse events that may be associated with the use of a medicinal product, even if these are already known or already reported on the reference documents of the product (e.g. package leaflet). Potential drug associated adverse events includes also situations different from the drug use approved conditions.

To report a potential adverse event occurred with the use of a MIAT medicinal product, please choose from the following:

– fill in the appropriate form following the instructions at this link: www.aifa.gov.it/moduli-segnalazione-reazioni-avverse
– follow the Step-by-Step procedure on Vigifarmaco website www.vigifarmaco.it
– inform your physician or pharmacist, they will forward the report to the local health department
Alternatively, it is possible to directly inform the company about a possible adverse event associated to an MIAT product at the following contact details.

MIAT S.p.A. PHARMACOVIGILANCE CONTACTS

MIAT has appointed the company seQure S.r.l. to manage its Pharmacovigilance activities and Dr. Stefania De Santis as MIAT Pharmacovigilance Manager and QPPV. These are the contacts for Pharmacovigilance reports:

Dr. Stefania De Santis

Tel: +39 (6) 69318366
Mob: +39 3894547423
E-mail: pmc.pharmacovigilance@sequrelifesciences.com

If you require any further information, feel free to contact us

  • Read the Privacy Disclaimer Read now